Related Experiment Video
Updated: Aug 16, 2026
A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
Disparities in universal prenatal screening for group B streptococcus--North Carolina, 2002-2003
Insights
Group B Streptococcus (GBS) screening is recommended for pregnant women. Data shows screening rates were similar but lower for Hispanic women and those receiving care at clinics, indicating a need for targeted prevention efforts.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Health
- Infectious Disease Prevention
Background:
- Group B Streptococcus (GBS) is a primary cause of illness and death in newborns.
- Intrapartum antibiotics effectively prevent GBS transmission from mother to child.
- Universal prenatal GBS screening guidelines were established in 2002.
Purpose of the Study:
- To evaluate prenatal GBS screening uptake among pregnant women in North Carolina.
- To identify demographic and care-related disparities in GBS screening.
Main Methods:
- Analysis of North Carolina Pregnancy Risk Assessment Monitoring System (PRAMS) data from 2002-2003.
- Examined self-reported prenatal screening for GBS colonization.
Main Results:
- Prenatal GBS screening rates were 70% in 2002 and 74% in 2003.
- Hispanic women were less likely to report GBS screening.
- Women receiving prenatal care at hospitals or health department clinics reported lower screening rates.
Conclusions:
- Despite recommendations, disparities in GBS screening persist.
- Targeted education and prevention strategies are needed for underserved populations.
- Improving GBS screening access is crucial for neonatal health protection.
Abstract:
Group B streptococcus (GBS) is a leading cause of neonatal morbidity and mortality in the United States. Intrapartum antibiotics administered to women at risk for transmitting GBS to their newborns are effective in preventing perinatal GBS infection. In 2002, CDC, the American Academy of Pediatrics, and the American College of Obstetricians and Gynecologists recommended universal prenatal screening for vaginal and rectal GBS colonization at 35-37 weeks' gestation. To examine prenatal GBS screening among pregnant women in North Carolina, CDC analyzed 2002 and 2003 data from the North Carolina Pregnancy Risk Assessment Monitoring System (PRAMS). The proportions of women reporting prenatal screening for GBS were similar in 2002 and 2003 (70% and 74%, respectively); however, for both years, women of Hispanic ethnicity and women who received prenatal care at a hospital or health department clinic were less likely to report prenatal screening for GBS. These findings underscore the need to increase GBS-related education and prevention activities targeted to these populations.
Related Concept Videos
01:28Development of the Oral Microbiota
01:30Development of Human Microbiota